Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Stavropoulos

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Scandinavian Journal of Rheumatology|January 15, 2013
Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistanceT Dimitroulas, A Sandoo, J J J C S Veldhuijzen van Zanten, et al.
Rheumatology (Oxford, England)|November 30, 2007
Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic reviewG S Metsios, A Stavropoulos-Kalinoglou, J J C S Veldhuijzen van Zanten, et al.
Journal of Human Hypertension|October 26, 2007
Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritisV F Panoulas, K M J Douglas, H J Milionis, et al.
Rheumatology (Oxford, England)|August 21, 2007
Prevalence and associations of hypertension and its control in patients with rheumatoid arthritisV F Panoulas, K M J Douglas, H J Milionis, et al.
Journal of Human Hypertension|April 29, 2011
Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritisA Sandoo, V F Panoulas, T E Toms, et al.
Neurospine|July 2, 2024
Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current EvidenceJordan J Levett, Miltiadis Georgiopoulos, Simon Martel, et al.
Anticancer Research|November 28, 2008
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoJoann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, et al.
Clinical Rheumatology|March 6, 2023
Barriers and facilitators for physical activity in rheumatic and musculoskeletal disease: a European-based surveyGeorge S Metsios, S A M Fenton, K Tzika, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Scandinavian Journal of Rheumatology|January 15, 2013
Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistanceT Dimitroulas, A Sandoo, J J J C S Veldhuijzen van Zanten, et al.
Rheumatology (Oxford, England)|November 30, 2007
Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic reviewG S Metsios, A Stavropoulos-Kalinoglou, J J C S Veldhuijzen van Zanten, et al.
Journal of Human Hypertension|October 26, 2007
Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritisV F Panoulas, K M J Douglas, H J Milionis, et al.
Rheumatology (Oxford, England)|August 21, 2007
Prevalence and associations of hypertension and its control in patients with rheumatoid arthritisV F Panoulas, K M J Douglas, H J Milionis, et al.
Journal of Human Hypertension|April 29, 2011
Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritisA Sandoo, V F Panoulas, T E Toms, et al.
Neurospine|July 2, 2024
Pharmacological Treatment of Degenerative Cervical Myelopathy: A Critical Review of Current EvidenceJordan J Levett, Miltiadis Georgiopoulos, Simon Martel, et al.
Anticancer Research|November 28, 2008
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivoJoann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, et al.
Clinical Rheumatology|March 6, 2023
Barriers and facilitators for physical activity in rheumatic and musculoskeletal disease: a European-based surveyGeorge S Metsios, S A M Fenton, K Tzika, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.
Pageof 10